J Korean Soc Pediatr Endocrinol Search

CLOSE


Ann Pediatr Endocrinol Metab > Accepted Articles
DOI: https://doi.org/10.6065/apem.2448202.101    [Accepted] Published online January 15, 2025.
Long-acting growth hormones: innovations in treatment and guidance on patient selection in pediatric growth hormone deficiency
Chiara Rodaro1  , Gianluca Tamaro2  , Elena Faleschini2  , Gianluca Tornese1,2 
1Department of Medicine, Surgery and Health Science, University of Trieste, Trieste, Italy
2Institute for maternal and child health IRCCS Burlo Garofolo, Trieste, Italy
Address for correspondence:  Gianluca Tornese
Email: gianluca.tornese@burlo.trieste.it
Received: August 15, 2024   Revised: November 13, 2024   Accepted: December 10, 2024
Abstract
Long-acting growth hormones (LAGHs) represent a significant advancement in the treatment of pediatric growth hormone deficiency (GHD), offering an alternative to daily recombinant human growth hormone (rhGH) therapy. Traditional rhGH treatments, while effective, require daily injections, often leading to poor adherence due to the frequency of dosing, injection pain, and difficulties with storage and travel. In contrast, LAGHs, such as somatrogon, somapacitan, and lonapegsomatropin, are designed for once-weekly administration, improving patient compliance and quality of life. LAGHs have demonstrated non-inferiority to daily rhGH in phase 3 clinical trials, showing similar efficacy in terms of growth velocity and safety profiles. Despite these advantages, there remain concerns regarding the altered pharmacodynamics of LAGHs, such as the lack of pulsatile secretion and the potential for antibody formation. While the overall safety of LAGHs has been confirmed, some side effects, like lipoatrophy at the injection site, may occur, especially with PEGylated formulations. Guidelines for prescribing LAGHs are still evolving.. They are not yet approved for other conditions traditionally treated with rhGH, such as Turner or Noonan syndrome. Pediatric endocrinologists must carefully consider which patient groups would benefit most from this therapy, particularly those at risk for poor adherence to daily injections, such as patients undergoing multi-drug therapy, patients with needle phobia or behavioral disorders, very young children, adolescents, patients with separated parents, families that travel frequently, or children involved in activities like scouting. LAGHs present an opportunity to enhance therapeutic outcomes and adherence, but careful patient selection remains critical to maximizing their potential benefits.
Keywords: Growth hormone, Dwarfism, Pituitary, Hypopituitarism, Patient selection, Child, Humans


ABOUT
ARTICLE CATEGORY

Browse all articles >

BROWSE ARTICLES
AUTHOR INFORMATION
Editorial Office
501-107, 30 Seocho-daero 74-gil, Seocho-gu, Seoul 06622, Republic of Korea
Tel: +82-2-3471-4268    Fax: +82-2-3471-4269    E-mail: editor@e-apem.org                

Copyright © 2025 by Korean Society of Pediatric Endocrinology.

Developed in M2PI

Close layer
prev next